A New Recombinant Tuberculosis Vaccine Safety Studies

 
PIIS102872210002645-4-1
DOI10.31857/S102872210002645-4
Publication type Article
Status Published
Authors
Affiliation:
Affiliation:
Affiliation:
Affiliation:
Affiliation:
Affiliation:
Affiliation:
Affiliation:
Affiliation:
Affiliation:
Affiliation:
Affiliation:
Affiliation:
Journal nameRossiiskii immunologicheskii zhurnal
EditionVolume 12 Issue 4
Pages704-706
Abstract

  

Keywords
Received30.01.2019
Publication date31.01.2019
Cite   Download pdf To download PDF you should sign in
Размещенный ниже текст является ознакомительной версией и может не соответствовать печатной

views: 1084

Readers community rating: votes 0

1. Global Tuberculosis Report, 2016, WHO.

2. Simbirtsev A. S., Dukhovlinov I. V., Dobrovol'skaya O. A., Fedorova E. A., Vaktsina protiv tuberkuleza, patent № 2 647 831, data prioriteta 15.03.2017, data publikatsii 19.03.2018. [Simbirtsev A. S., Dukhovlinov I. V., Dobrovolskaya O. A, Fedorova E. A. Tuberculosis Vaccine. Patent 2 647 831, Priority Date 15.03.2017, Published 19.03.2018].

3. GOST R 56699–2015. Lekarstvennye sredstva dlya meditsinskogo primeneniya. Doklinicheskie issledovaniya bezopasnosti biotekhnologicheskikh lekarstvennykh preparatov. Obschie rekomendatsii. Moskva, Standartinform, 2016. [GOST R56699–2015. Medicinal Products for Human. Preclinical Safety Studies of Biotech Medicinal Products. General Recommendations. Moskva. Standartinform, 2016].

Система Orphus

Loading...
Up